Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib combinations for recurrent brain metastases from HER2-positive breast cancer after cranial radiotherapy
2006-005912-28Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib, capecitabine and topotecan in breast cancer and brain metastases (2 arms), sponsored by GSK. Primary endpoint: CNS objective response rate. Started Feb 2007; status: completed.
02
Drugs
lapatinibcapecitabinetopotecan
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2006-005912-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005912-28.